Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies: a Phase III Randomized Study

NCT07193420 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT07193420
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07193420 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reduced Post-transplant Cyclophosphamide Dose in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation for Hematological Malignancies: a Phase III Randomized Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Phase 3
Overall status
Not yet recruiting
Start date
June 30, 2026
Completion date
June 30, 2030
Enrollment
180 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gvhd - graft-versus-host disease, haploidentical stem cell transplantation, hsct